blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2560644

EP2560644 - A PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENTS AND AN ERYTHROPOIESIS STIMULATING AGENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.05.2017
Database last updated on 26.07.2024
Most recent event   Tooltip15.11.2019Lapse of the patent in a contracting state
New state(s): MK		published on 18.12.2019  [2019/51]
Applicant(s)For all designated states
Cadila Healthcare Limited
Zydus Tower Satellite Cross Roads
Ahmedabad 380 015 Gujarat / IN
[2016/26]
Former [2013/09]For all designated states
Cadila Healthcare Limited
Zydus Tower Satellite Cross Roads
Ahmedabad 380 015 Gujarat / IN
Inventor(s)01 / SONI, Hitesh, Madanlal
Zydus Tower
Satellite Cross Road
Ahmedabad 380 015 Gujarat / IN
02 / JAIN, Mukul, R.
Zydus Tower
Satellite Cross Road
Ahmedabad 380 015 Gujarat / IN
 [2013/09]
Representative(s)Zacco Denmark A/S
Arne Jacobsens Allé 15
2300 Copenhagen S / DK
[2016/26]
Former [2014/45]Zacco Sweden AB
Valhallavägen 117
P.O. Box 5581
114 85 Stockholm / SE
Former [2013/09]Verboom, Renzo Christiaan
Zacco Sweden AB
P.O. Box 5581
114 85 Stockholm / SE
Application number, filing date11736457.018.04.2011
[2016/26]
WO2011IN00259
Priority number, dateIN2010MUM128119.04.2010         Original published format: IN 1281MU2010
[2017/16]
Former [2013/09]IN2010MUM128119.04.2010
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011132201
Date:27.10.2011
Language:EN
[2011/43]
Type: A1 Application with search report 
No.:EP2560644
Date:27.02.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 27.10.2011 takes the place of the publication of the European patent application.
[2013/09]
Type: B1 Patent specification 
No.:EP2560644
Date:29.06.2016
Language:EN
[2016/26]
Search report(s)International search report - published on:EP27.10.2011
ClassificationIPC:A61K31/4365, A61K31/60, A61K38/18, A61P13/12, A61K45/06, A61K31/381, A61K31/616
[2016/03]
CPC:
A61K38/1816 (EP,US); A61K31/381 (EP,US); A61K31/4365 (EP,US);
A61K31/616 (EP,US); A61K45/06 (EP,US); A61P13/12 (EP)
C-Set:
A61K31/381, A61K2300/00 (EP,US);
A61K31/4365, A61K2300/00 (US,EP);
A61K31/616, A61K2300/00 (US,EP);
A61K38/1816, A61K2300/00 (US,EP)
Former IPC [2013/09]A61K31/4365, A61K31/60, A61K38/18, A61P13/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/09]
Extension statesBA16.11.2012
ME16.11.2012
TitleGerman:PHARMAZEUTISCHE ZUBEREITUNG ENTHALTEND THROMBOZYTENHEMMER UND EINE ERYTHROPOIESE STIMULIERENDE VERBINDUNG[2016/03]
English:A PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENTS AND AN ERYTHROPOIESIS STIMULATING AGENT[2013/09]
French:COMPOSITION PHARMACEUTIQUE COMPRENANT DES AGENTS ANTIPLAQUETTAIRES ET UN AGENT STIMULANT L'ÉRYTHROPOÏÈSE[2016/03]
Former [2013/09]PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT THROMBOZYTENHEMMERN UND EINEM ERYTHROPOESESTIMULATOR
Former [2013/09]COMPOSITION PHARMACEUTIQUE COMPRENANT DES ANTIPLAQUETTAIRES ET UN STIMULATEUR DE L'ÉRYTHROPOÏÈSE
Entry into regional phase16.11.2012National basic fee paid 
16.11.2012Designation fee(s) paid 
16.11.2012Examination fee paid 
Examination procedure03.11.2011Request for preliminary examination filed
International Preliminary Examining Authority: EP
16.11.2012Examination requested  [2013/09]
28.05.2013Amendment by applicant (claims and/or description)
04.03.2015Despatch of a communication from the examining division (Time limit: M04)
03.07.2015Reply to a communication from the examining division
22.01.2016Communication of intention to grant the patent
20.05.2016Fee for grant paid
20.05.2016Fee for publishing/printing paid
20.05.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.03.2015
Opposition(s)30.03.2017No opposition filed within time limit [2017/23]
Fees paidRenewal fee
22.04.2013Renewal fee patent year 03
21.03.2014Renewal fee patent year 04
21.04.2015Renewal fee patent year 05
29.03.2016Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.04.2011
AL29.06.2016
AT29.06.2016
BE29.06.2016
CY29.06.2016
CZ29.06.2016
DK29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
MK29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
BG29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
[2019/51]
Former [2019/46]HU18.04.2011
AL29.06.2016
AT29.06.2016
BE29.06.2016
CY29.06.2016
CZ29.06.2016
DK29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
BG29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2019/31]HU18.04.2011
AL29.06.2016
AT29.06.2016
BE29.06.2016
CZ29.06.2016
DK29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
BG29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2018/46]AL29.06.2016
AT29.06.2016
BE29.06.2016
CZ29.06.2016
DK29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
BG29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2018/06]AT29.06.2016
BE29.06.2016
CZ29.06.2016
DK29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
BG29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/38]AT29.06.2016
BE29.06.2016
CZ29.06.2016
DK29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
BG29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/11]AT29.06.2016
BE29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SK29.06.2016
SM29.06.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/10]BE29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SK29.06.2016
GR30.09.2016
IS29.10.2016
Former [2017/09]CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RO29.06.2016
RS29.06.2016
GR30.09.2016
Former [2016/51]FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RS29.06.2016
GR30.09.2016
Former [2016/50]FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RS29.06.2016
Former [2016/49]FI29.06.2016
LT29.06.2016
Former [2016/46]LT29.06.2016
Cited inInternational search[XY]US6521245  (ZAHARIA VERONICA L CZEIZLER [US]) [X] 13-15,17 * column 4; example 1 * * column 6; example 6 and 7 * [Y] 1-18;
 [X]US2006094648  (STAMLER JONATHAN S [US]) [X] 1-18 * page 10, paragraph 112 * * claims 39-43 *;
 [X]  - TAYLOR J E ET AL, "ERYTHROPOIETIN AND SPONTANEOUS PLATELET AGGREGATION IN HAEMODIALYSIS PATIENTS", LANCET, (1991), vol. 338, no. 8779, ISSN 0099-5355, pages 1361 - 1362, XP002659824 [X] 1-18 * the whole document *
 [X]  - KOOISTRA M P ET AL, "Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, (19940101), vol. 9, no. 8, ISSN 0931-0509, pages 1115 - 1120, XP009090353 [X] 1-18 * abstract *
 [X]  - MESQUITA MARIA DO CARMO FILOMENA ET AL, "Management of Refractory Essential Thrombocythemia With Anagrelide in a Patient Undergoing Hemodialysis", CLINICAL THERAPEUTICS, (200911), vol. 31, no. 11, ISSN 0149-2918, pages 2559 - 2564, XP026872257 [X] 1-18 * the whole document *
 [XY]  - TANG Y D ET AL, "Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: Results of a double-blind, placebo-controlled, randomized trial", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 158, no. 6, doi:10.1016/J.AHJ.2009.06.032, ISSN 0002-8703, (20091201), pages 941 - 947, (20091201), XP026787882 [X] 13-15,17 * the whole document * [Y] 1-18

DOI:   http://dx.doi.org/10.1016/j.ahj.2009.06.032
by applicantUS4847265
 US6429210
 US6693115
    - GARCIA DL, PNAS, (1988), pages 6142 - 6146
    - SANOFI-AVENTIS, BMS, WWW.PLAVIX.COM AND NEJM, vol. 361, pages 940 - 942
    - NEJM, (2001), vol. 345, no. 7, pages 494 - 502
    - JAM SOC NEPHROL, (2003), vol. 14, pages 2313 - 2321
    - GARCIA DL ET AL., PNAS, (1988), pages 6142 - 6146
    - THROMB HAEMOST, (1997), vol. 78, pages 1505 - 09
    - BLOOD, (2000), vol. 95, pages 2983 - 89
    - CURR OPIN NEPHROL HYPERTENS, (2001), vol. 10, pages 633 - 77
    - BMJ, (1990), vol. 300, pages 573 - 8
    - N ENGL J MED, (1998), vol. 339, pages 584 - 90
    - CANCER, (2003), vol. 9, pages 1514 - 20
    - CLIN INVEST, (1994), vol. 72, pages S36 - S43
    - LANCET, (2007), vol. 369, pages 381 - 8
    - CLIN J AM SOC NEPHROL, (2007), vol. 2, pages 1274 - 82
    - AM J HYPERTENSION, (2006), vol. 19, pages 1286 - 1292
    - PNAS USA, (1988), vol. 85, pages 6142 - 6146
    - NEJM, vol. 351, pages 1296 - 1305
    - GOLDSTEIN SL., KIDNEY INTERNATIONAL, (2010), vol. 78, pages 433 - 435
    - DAMMAN K ET AL., EUR J HEART FAIL, (2007), vol. 6, pages 17 - 18
    - KHAN NA ET AL., J AM SOC NEPHROL, (2006), vol. 17, pages 244 - 253
    - KRUMHOLZ HM ET AL., AM J CARDIOL, (2000), vol. 85, pages 1110 - 1113
    - KIRKEBY A ET AL., THROMB HAEMOST, (2008), vol. 99, pages 720 - 728
    - TOBA H ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, (2011), vol. 656, pages 81 - 87
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.